See more on the latest on Soleno Therapeutics (SLNO) stock after VYKAT XR approval. Learn why post-approval commercialization ...
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...
Hosted on MSN
Soleno Therapeutics Shares Surge After Competitor’s Prader-Willi Treatment Misses Endpoint
Soleno Therapeutics (NASDAQ:SLNO) saw its stock climb 14% following news that Acadia Pharmaceuticals’ (NASDAQ:ACAD) Phase 3 trial for a Prader-Willi syndrome therapy failed to meet its primary ...
Soleno Therapeutics is breathing easier with a report from Acadia Pharmaceuticals that its candidate to treat hyperphagia in patients with Prader-Willi Syndrome (PWS) has come up short in a phase 3 ...
SGLT2 inhibitors significantly improved glycaemic control and reduced the albumin-to-creatinine ratio without affecting body weight in patients with Prader-Willi syndrome and type 2 diabetes (T2D); ...
Hosted on MSN
Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial
We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the top performers on Tuesday. Soleno Therapeutics extended its winning ...
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. ACADIA Pharmaceuticals Inc. stands second among them. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a ...
Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback